Infusion of a High Number of CD34+ Cells Provides a Rapid Hematopoietic Recovery and Cost Savings in Autologous Peripheral Blood Stem Cell Transplantation

• Published in: Japanese journal of clinical oncology 2002-04, Vol.32 (4), p.135-139
• Main Authors: Ashihara, Eishi, Shimazaki, Chihiro, Okano, Akira, Hatsuse, Mayumi, Okamoto, Akio, Shimura, Kazuho, Takahashi, Ryoichi, Sumikuma, Toshiya, Inaba, Tohru, Fujita, Naohisa, Murakami, Satoshi, Haruyama, Harue, Nakagawa, Masao
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antigens, CD34 - analysis; Blood Component Transfusion; Blood Transfusion, Autologous; Cost-Benefit Analysis; Female; Hematologic Neoplasms - economics; Hematologic Neoplasms - therapy; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Key words: CD34+ cells – autologous PBSCT – economic analysis – hematopoietic recovery; Male; Middle Aged; Neutrophils - immunology; Neutrophils - transplantation; Platelet Transfusion
• ISSN: 0368-2811; 1465-3621; 1465-3621
• DOI: 10.1093/jjco/hyf030

Background: The objectives of this study were to evaluate the effect of the number of infused CD34+ cells on hematopoietic recovery and on the cost in autologous peripheral blood stem cell transplantation (PBSCT). Methods: Sixty-nine patients who received autologous PBSCT (ABSCT) were divided into three groups defined by the number of infused CD34+ cells. The number of days until 0.5 × 109/l neutrophils and 50 × 109/l platelets, the number of transfused blood products, the febrile days, the duration of parenteral antibiotics and the cost of additional supportive care (transfusions of blood products and parenteral antibiotics) were analyzed. Results: Twenty-three patients received